Renovacor

🗓 Founded 2019👥 10 employees💰 Last funded Sep 2021
Biotechnology Research🌐 renovacor.com
Website LinkedIn
Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases. The company’s lead program in BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer technology to address the monogenic cause of this severe form of heart failure. Renovacor’s vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases, by developing medicines that target the underlying cause of disease and provide a transformative benefit and significant improvement to quality of life.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Italy
1
Frequently asked questions
Who invested in Renovacor?
Renovacor has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Renovacor last raise funding?
The most recent investment in Renovacor recorded on gritt.io was in September 2021.
When was Renovacor founded?
Renovacor was founded in 2019.
What industry is Renovacor in?
Renovacor operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.